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It is commonly thought that autoimmune diseases are caused by the breakdown of self-
tolerance, which suggests the recognition of speciﬁc antigens by autoreactive CD4+
T cells contribute to the speciﬁcity of autoimmune diseases (Marrack et al., 2001; Mathis
and Benoist, 2004). In several cases, however, even for diseases associated with class
II major histocompatibility complex (MHC) alleles, the causative tissue-speciﬁc antigens
recognized by memory/activated CD4+ T cells have not been established (Mocci et al.,
2000; Skapenko et al., 2005). Rheumatoid arthritis (RA) and arthritis in F759 knock-in
mice (F759 mice) are such examples (Atsumi et al., 2002; Brennan et al., 2002; Falgarone
et al., 2009). These include associations with class II MHC and CD4 molecules; increased
numbers of memory/activated CD4+T cells; and improved outcomes in response to sup-
pressions and/or deﬁciencies in class II MHC molecules, CD4+ T cells, and the T cell
survival cytokine IL-7. Regarding the development of arthritis in F759 mice, it is not only
the immune system, but also non-immune tissue that are involved, indicating that the
importance of their interactions (Sawa et al., 2006, 2009; Ogura et al., 2008; Hirano, 2010;
Murakami et al., 2011). Furthermore, we have shown that local events such as microbleed-
ing together with an accumulation of activated CD4+ T cells in a manner independent of
tissue antigen-recognitions induces arthritis in the joints of F759 mice (Murakami et al.,
2011). For example, local microbleeding-mediated CCL20 expression induce such an accu-
mulation, causing arthritis development via chronic activation of an IL-17A-dependent IL-6
signaling ampliﬁcation loop in type 1 collagen+ cells that is triggered by CD4+T cell-derived
cytokine(s) such as IL-17A, which leads to the synergistic activation of STAT3 and NFκB in
non-hematopoietic cells in the joint (Murakami et al., 2011). We named this loop the IL-
6-mediated inﬂammation ampliﬁer, or IL-6 ampliﬁer for short (Ogura et al., 2008; Hirano,
2010; Murakami et al., 2011).Thus, certain class II MHC-associated, tissue-speciﬁc autoim-
mune diseases, including some RA subtypes, may be induced by local events that cause
an antigen-independent accumulation of effector CD4+ T cells followed by the induction
of the IL-6 ampliﬁer in the affected tissue. In other words, in certain cases, the target
tissue itself may determine the speciﬁcity of the autoimmune disease via activation of
the IL-6 ampliﬁer. To explain this hypothesis, we have proposed a four-step model for
MHC class II-associated autoimmune diseases (Murakami et al., 2011): (1) T cell activation
regardless of antigen speciﬁcity; (2) local events inducing a tissue-speciﬁc accumulation
of activated T cells; (3) transient activation of the IL-6 ampliﬁer; and (4) enhanced sensi-
tivity to cytokines in the target tissue. The interaction of these events results in chronic
activation of the IL-6 ampliﬁer and subsequent manifestation of autoimmune diseases.
Thus, the IL-6 ampliﬁer, which is chronically activated by these four events, is a critical
regulator of chronic inﬂammations in tissue-speciﬁc MHC class II-associated autoimmune
diseases.
Keywords: MHC class II association, autoimmune diseases, inflammation, IL-6-mediated inflammation amplifier,
cytokines, chemokines,Th17 cells
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TISSUE-SPECIFIC MHC CLASS II-ASSOCIATED
AUTOIMMUNE DISEASES AND ANTIGEN-RECOGNITIONS BY
CD4+ T CELLS
It has been proposed that autoimmune diseases are caused by a
breakdown of self-tolerance due to multiple genetic and/or envi-
ronmental factors (Marrack et al., 2001;Mathis andBenoist, 2004),
suggesting the dysregulation of immune responses is fundamental
to autoimmune diseases. This agrees with the theory that cer-
tain autoimmune diseases like rheumatoid arthritis (RA) develop
in speciﬁc tissues as a result of cognate antigen-recognition by
CD4+ T cells, particularly when these diseases are associated with
class II major histocompatibility complex (MHC) alleles (Stein-
man, 2001; Zhang et al., 2008; Imboden, 2009). Consistent with
this, joint-speciﬁc antigenic peptides such as derivatives of aggre-
can, ﬁbrillin, and collagen have been identiﬁed in humans (Polgár
et al., 2003; Chapuy-Regaud et al., 2005; Takizawa et al., 2006; Van
Steendam et al., 2010),while immunodominantMHCclass II pep-
tides in an animal model have been found to match those seen in
human RA (Andersson et al., 2010). However, it is unclear whether
these peptides are a result or cause of joint damage.Despite the evi-
dence for antigen-speciﬁc T cell activation in some RA patients,
tissue-speciﬁc self or non-self antigens recognized by activated
CD4+ T cells in many class II MHC-associated diseases and even
a majority of RA cases have not been well-established (Mocci et al.,
2000; Skapenko et al., 2005). This raises the possibility that a break-
down in CD4+ T cell tolerance for a tissue-speciﬁc antigen is not
always necessary for tissue-speciﬁc autoimmune diseases. Instead,
it may be the consequence of local events that are initiated by
inﬂammation triggered by certain genetic and/or environmental
factors (Hirano, 1998, 2010;Matsumoto et al., 1999;Marrack et al.,
2001; Sawa et al., 2006) such that the speciﬁcity of an autoimmune
disease could be determined by the non-immune target tissue itself
(Brennan et al., 2002; Hirano, 2002). In these cases, CD4+T cells
may act as the source for a variety of inﬂammatory cytokines
(Brennan et al., 2002). In fact, various subsets of effector CD4+
T cells – e.g., T helper 1 (Th1) cells, Th2 cells, and Th17 cells,
which produce IFNγ, IL-4, and IL-17A, respectively (Mosmann
and Coffman, 1989; Glimcher and Murphy, 2000; Cua et al., 2003;
Harrington et al., 2005; Park et al., 2005;Veldhoen et al., 2006; Zhu
et al., 2006; Bettelli et al., 2007; Nishihara et al., 2007) – may ini-
tiate and drive the progression of disease. This may help explain
why RA is more common in older populations, as there exists
an age-dependent increase in memory/activated CD4+ T cells
resulting from a homeostatic proliferation that is mediated by a
reduction in T cell input from the thymus (Surh and Sprent, 2000).
Moreover, it has been reported that an age-dependent reduction
in naive CD4+ T cells in peripheral second lymphoid organs
increases the likelihood of (i) weak interactions between TCRs
and peptides presented by self-class II MHC molecules includ-
ing auto-antigenic peptides involved in positive selections in the
thymus and (ii) cytokine consumption per CD4+ T cell includ-
ing the T cell survival factor IL-7 (Surh and Sprent, 2000). This
could help explain the occurrence of other diseases too, as the
homeostatic proliferation of CD4+ T cells has been shown to be
involved in the development of diabetes, arthritis, and Omenn
syndrome (King et al., 2004; Jang et al., 2006; Sawa et al., 2006;
Khiong et al., 2007). This process is also associated with a speciﬁc
cytokine proﬁle that includes the IL-17A and IFNγ produced by
CD4+ T cells (Gudmundsdottir and Turka, 2001; Khiong et al.,
2007; Nishihara et al., 2007).
IL-6 IN AUTOIMMUNE DISEASES
IL-6 is a pleiotropic cytokine that regulates multiple biolog-
ical processes including the development of the nervous and
hematopoietic systems, acute-phase responses, inﬂammation, and
immune responses (Hirano, 1998). To date, 10 IL-6 family
cytokines have been identiﬁed: IL-6, oncostatin M, LIF, CNTF,
CT-1, NNT-1, neuropoietin, IL-11, IL-27, and IL-31 (Kamimura
et al., 2003;Murakami et al., 2004; Suthaus et al., 2010). All of these
share gp130 as the signal transducer in their receptor complexes.
Upon IL-6 stimulation, gp130 transduces two major signaling
pathways: the JAK–signal transducer and activator of transcription
3 (STAT3) pathway,which ismediated by theYxxQmotif of gp130,
and the SHP2–Gab-Ras-Erk–MAPK pathway, which is regulated
by Y759, a cytoplasmic SOCS3 binding residue in gp130 (Fukada
et al., 1996; Ohtani et al., 2000; Kamimura et al., 2003). Addition-
ally, a number of studies have suggested IL-6 has an important role
in autoimmune diseases (Hirano, 1998, 2010; O’Shea et al., 2002;
Sakaguchi and Sakaguchi, 2005; Awasthi and Kuchroo, 2009). The
F759 knock-in mouse line (F759), for example, which expresses a
mutant variant of gp130 where Y759 is substituted for phenylala-
nine (F), shows enhanced IL-6-mediated STAT3 activation due to a
lack of SOCS3-mediated suppression (Ohtani et al., 2000).As these
mice age, they spontaneously develop a RA-like tissue-speciﬁc
disease, indicating that constitutive activation of IL-6 signaling
is involved in the development of certain autoimmune diseases
(Atsumi et al., 2002). Moreover, patients with RA show high syn-
ovial concentrations of IL-6 (Hirano et al., 1988), while anti-IL-6
receptor therapy is effective for some RA patients (Nakagawa et al.,
2010). These observations support the use of the F759 mouse as
a murine model for RA. Furthermore, we have previously shown
that MHC II-restricted CD4+ T cells, but not CD8+ T cells and
B cells, are involved in the development of arthritis in F759 mice
(Sawa et al., 2006), while a subset of CD8+ T cells that express
Foxp3 and are induced by IL-6 signaling suppress it (Nakagawa
et al., 2010).
AN IL-17A-DEPENDENT IL-6 SIGNALING AMPLIFICATION
LOOP IN TYPE 1 COLLAGEN+ CELLS, THE IL-6 AMPLIFIER,
PLAYS A ROLE IN THE DEVELOPMENT OF MHC CLASS
II-ASSOCIATED AUTOIMMUNE DISEASES
While CD4+T cells are required for F759 arthritis, bone mar-
row transplantation experiments have demonstrated the F759
mutation in non-hematopoietic cells is sufﬁcient for F759 arthri-
tis without any accompanying mutation in the CD4+ T cells
(Sawa et al., 2006). This shows that an interaction between non-
immune tissues/cells and the immune system plays a critical role
this andmost likely several other autoimmune and chronic inﬂam-
matory diseases (Hirano, 1998, 2010). Our detailed experiments
utilizing bone marrow chimera mice and knock-out mice fur-
ther demonstrate that excess IL-6 signaling in non-hematopoietic
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cells, particularly type 1 collagen+ cells, due to the F759 muta-
tion induces an enhanced production of the T cell survival factor
IL-7, which increases memory/activated CD4+ T cells via an
increase in homeostatic proliferation – a process that is criti-
cal for arthritis development in F759 mice (Sawa et al., 2006).
Furthermore, IL-17A-expressing CD4+ T cells show a mem-
ory/activated phenotype in vivo in F759 mice, while IL-17A reg-
ulates their arthritis (Ogura et al., 2008; Murakami et al., 2011).
Thus, it is plausible that the age-dependent increase in homeo-
static proliferation via IL-6-mediated IL-7 expression plays a role
in the accumulation of antigen-experienced, memory/activated
CD4+ T cells expressing IL-17A. This is especially true for
those F759 mice that show excess IL-6 signaling. We previously
showed that IL-17A-triggerred positive feedback of IL-6 signal-
ing, which results in synergistic hyper-expressions of chemokines
and IL-6 itself in type 1 collagen+ cells, is enhanced in a man-
ner dependent on NF-κB and STAT3, which our themselves
stimulated by IL-17A in the presence of an IL-6 signal (Ogura
et al., 2008; Figure 1). We named this IL-17A-dependent IL-6
signaling ampliﬁcation loop in type 1 collagen+ cells the IL-
6-mediated inﬂammation ampliﬁer, or IL-6 ampliﬁer for short
(Ogura et al., 2008; Hirano, 2010). Furthermore, activation of
the IL-6 ampliﬁer is critical not only for the development of
arthritis in F759 mice but also for MOG antigen-speciﬁc, T cell-
mediated experimental autoimmune encephalomyelitis (EAE;
Ogura et al., 2008). These results further support the idea that
interactions between the immune system and non-immune tis-
sue play roles in the development of autoimmune diseases and
that the IL-6 ampliﬁer makes a major contribution to this
interaction.
A FOUR-STEP MODEL EXPLAINS THE CHRONIC ACTIVATION
OF THE IL-6 AMPLIFIER THAT IS FOLLOWED BY THE
DEVELOPMENT OF MHC CLASS II-ASSOCIATED
AUTOIMMUNE DISEASES
Because CD4+ T cells bearing a single TCR that recognizes anti-
gens not related to joint tissue induces arthritis in Rag2 deﬁcient
mice that have the F759 mutation, we concluded that cognate
antigen-recognition by effector CD4+ T cells is not necessary for
tissue speciﬁcity in F759 mice (Murakami et al., 2011). From this,
we hypothesized that disease speciﬁcity may be determined by the
tissue itself such that local events in the joint may determine and
initiate the disease via the IL-6 ampliﬁer. For example, intravenous
transfer of in vitro polarized Th17 cells into young F759 mice does
not develop arthritis within 3 months. This sharply contrasts with
the case where MOG antigen-speciﬁc Th17 transfer induces EAE.
However, if Th17 cell transfer is done before inducing experimen-
tal microbleeding in one leg of F759 mice, then this leg and only
this leg will develop arthritis. Even Th17 cells derived from TCR
transgenic mice induced arthritis in the microbleeding-induced
leg of F759 mice. These ﬁndings are consistent with the idea that
local events determine the disease speciﬁcity even if activation of
tissue antigen-speciﬁc T cells does not occur. We further observed
that T cells accumulate in the joint where arthritis occurs. This
microbleeding-induced accumulation of Th17 cells is dependent
on the production of CCL20, a target of the IL-6 ampliﬁer, in
FIGURE 1 | IL-6 amplifier activation plays a role in the development of
autoimmune diseases such as arthritis in F759 mice and EAE.
IL-17A-triggerred positive feedback of IL-6 signaling, which results in
synergistic hyper-expressions of chemokines and IL-6 itself in type 1
collagen+ cells, is enhanced in a manner dependent on NF-κB and STAT3,
which our themselves stimulated by IL-17A in the presence of an IL-6 signal
(bar graph). We named this IL-17A-dependent IL-6 signaling ampliﬁcation loop
in type 1 collagen+ cells the IL-6-mediated inﬂammation ampliﬁer, or IL-6
ampliﬁer for short. Importantly, activation of the IL-6 ampliﬁer is critical not
only for the development of arthritis in F759 mice but also for MOG
antigen-speciﬁc, T cell-mediated experimental autoimmune encephalomyelitis
(EAE; Ogura et al., 2008).
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the joint. Disease induction requires T cell produced IL-17A, IL-6,
and enhanced STAT3 signaling in type I collagen-expressing cells
(Murakami et al., 2011). Based on these results, we propose that
certain class II MHC-associated autoimmune diseases such as RA
arise through a series of at least four steps (Figure 2): (1) T cell
activation regardless of antigen speciﬁcity; (2) local events induc-
ing a tissue-speciﬁc accumulation of activated T cells; (3) transient
activation of the IL-6 ampliﬁer,which is triggered by CD4+ T cell-
derived cytokines such as IL-17A; and (4) enhanced sensitivity to
T cell-derived cytokines and/or IL-6 in type 1 collagen+ cells in the
target tissue. After these four steps, chronic activation of the IL-6
ampliﬁer followed by the development of an autoimmune disease
occurs. It is likely that each step interacts with the others, and
the degree of the contribution of each to the pathogenesis varies
with the disease. Our four-step model provides a plausible expla-
nation for why tissue-speciﬁc antigens recognized by activated
CD4+ T cells have not been identiﬁed in several autoimmune dis-
eases, especially those associated with class II MHC molecules. It
is likely that in diseases where tissue antigen-speciﬁc T cells play
roles, tissue antigen-speciﬁc recognition by T cells would bypass
the requirement of local events, even though these local events can
still affect the accumulation of tissue antigen-speciﬁc T cells in the
target tissue. Our four-step model, therefore, should be applicable
to a wide range of autoimmune and other chronic inﬂammatory
diseases (see last section).
CHRONIC ACTIVATION OF THE IL-6 AMPLIFIER CAN
OVERRIDE HOMEOSTASIS IN TARGET TISSUES
The number of cytokine-secreting effector/memory CD4+ T cells
increases with age due to an accumulation of pathogen-speciﬁc
memory T cells and homeostatic proliferation of CD4+ T cells.
These CD4+ T cells are increasingly localized in parenchymal
organs like the alimentary tract, lung, and liver, rather than
the lymphoid organs, meaning at steady state, memory/activated
CD4+ T cells may migrate to and/or stay in non-lymphoid tis-
sues that are at high risk for autoimmune diseases. Consistent
with this, these diseases are more prevalent in older patients who
have a larger population of memory/activated CD4+ T cells,
some of which secrete cytokines because of homeostatic prolif-
eration and/or chronic inﬂammations in other tissues (Hasler
and Zouali, 2005; Larbi et al., 2008). Therefore, the ﬁrst three
steps will occur to some extent even in healthy subjects, although
the degree will differ among individuals (see Figure 2). Autoim-
mune diseases like RA, however, do not develop in all individuals.
Therefore, the relatively low rates of these disorders may reﬂect
the fact that multiple genetic and environmental factors make a
FIGURE 2 | A four-step model for MHC class II-associated autoimmune
diseases. Certain class II MHC-associated autoimmune diseases arise
through a series of four steps: (1) T cell activation regardless of antigen
speciﬁcity; (2) local events inducing a tissue-speciﬁc accumulation of
activatedT cells; (3) transient activation of the IL-6 ampliﬁer, which is
triggered by CD4+T cell-derived cytokines such as IL-17A; and (4)
enhanced sensitivity to T cell-derived cytokines and/or IL-6 in type 1
collagen+ cells in the target tissue. Following these four steps, chronic
activation of the IL-6 ampliﬁer followed by the development of an autoimmune
disease occurs. It is likely that each step interacts with the others, and the
degree of the contribution of each to the pathogenesis varies with the
disease.
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signiﬁcant contribution, particularly at the fourth step, for disease
development.
POTENTIAL FACTORS THAT ACCELERATE TISSUE
SENSITIVITY TO CYTOKINES INVOLVED IN AUTOIMMUNE
DISEASES
Because the activation of the IL-6 ampliﬁer is mediated by the syn-
ergistic activation of NF-κB and STAT3 molecules, we hypothesize
factors that stimulate the signaling pathways regulating these two
molecules in non-immune tissues/cells play a role in the devel-
opment of MHC class II-associated autoimmune diseases and
possibly other chronic inﬂammatory diseases (Hasler and Zouali,
2005; Larbi et al., 2008). These factors and the role of their cognate
recognitions in CD4+ T cells are discussed below.
VIRUS/BACTERIA PRODUCTS AND EXOGENOUS TLR STIMULATORS
One example is products made by viruses or bacteria (Münz et al.,
2009). For instance, HTLV1 infection is a signiﬁcant risk factor
for arthritis (Ishihara et al., 2004), while the transgenic expres-
sion of p40 Tax, a product of HTLV1 that activates NF-κB, causes
a RA-like disease in mice (Iwakura et al., 1991). Indeed, forced
expression of p40 Tax in F759 mice has been seen to enhance
disease development (Ishihara et al., 2004). Moreover, many viral
proteins, including the hepatitis C virus Core protein and EBNA2
from the Epstein–Barr virus, are strong STAT3 activators (Yoshida
et al., 2002; Muromoto et al., 2009). Products from pathogens are
also known to stimulate Toll-like receptors that lead to NF-κB
activation. Since viruses and bacteria also have their own prefer-
ential target cells and/or tissues, their infections could determine
the tissue speciﬁcity of a disease by enhancing cytokine sensitivity
in the given tissue. Consistent with this, autoimmune diseases are
sometimes induced after infections that also increase the number
of activated, pathogen-speciﬁc, cytokine-secreting CD4+ T cells
(Kivity et al., 2009).
MICROBLEEDING AND MECHANICAL STRESS IN THE TISSUES
Microbleeding in the joints may result in the accumulation of
many different cell types including red blood cells, neutrophils,
macrophages, and dendritic cells as well as memory/activated
CD4+ T cells including Th17 cells. Here we focused on IL-17A
expression from Th17 cells accumulating in the joints. However,
one can argue that microbleeding can accelerate the inﬂamma-
tory reaction by other means. For example, the environment of
the joint synovium or the presence of dead cells may lead to the
release of intracellular stimulants such as heme and/or danger-
associated molecular patterns (DAMPs; Zhang et al., 2010). These
stimulants secondarily enhance cell death by heme’s toxic effect.
They might also induce IL-6 and/or CCL20 expression based on
the fact that DAMPs can activate the NF-κB pathway (Bianchi,
2007; Sims et al., 2010).
Tissue sensitivity to mechanical stress that arises with age is
another potential trigger or enhancer for autoimmunediseases.We
have shown that an experimental compression enhances arthritis
development in F759 mice in the presence of Th17 cell transfer
(unpublished data), suggesting that such stress can induce local
events like microbleeding and/or IL-6 expression via activation of
NF-κB.
GENETIC FACTORS/MUTATIONS AFFECTING SIGNALING MOLECULES
IN NF-κB AND STAT3 PATHWAYS
Moreover, MHC class II-associated autoimmune diseases might
be associated with various genetic aberrations including a somatic
mutation in gp130 molecules that induces STAT3 hyperactivation,
andmutations inNF-κBand its regulators that lead todysregualted
NF-κB signaling (Lenz et al., 2008; Compagno et al., 2009;
Rebouissou et al., 2009). This may not apply in humans, however,
as to date we have not identiﬁed mutations in the cytoplasmic
region of gp130 in patients. Nevertheless, there still remains evi-
dence that STAT3 abnormalities are involved, as demonstrated
in the B cells of patients with hyper-immunoglobulin E syn-
drome (Minegishi et al., 2007). Because F759 mice lack SOCS3-
mediated negative feedback only in the gp130 signaling pathway, it
is reasonable to speculate that speciﬁcally deleting SOCS3 in non-
hematopoietic cells could also increase the risk of autoimmune
and/or other chronic inﬂammatory diseases. Consistent with this
notion, SOCS3 deﬁciency in liver cells increased the degree of liver
ﬁbrosis (Ogata et al., 2006). Although this phenotype is should not
be classiﬁed speciﬁcally as an autoimmune syndrome, the ﬁbro-
sis likely mirrors the effects of NF-κB/STAT3 mutations. Finally,
dysregulated NF-κB/STAT3 activation in non-immune cells such
as type I collagen+ ﬁbroblasts may trigger a feedback loop that
increases IL-6 expression to induce inﬂammation like that seen in
F759 mice.
ROLE OF OTHER CYTOKINES DERIVED FROM CD4+ T CELLS
Cytokines other than IL-17A may also contribute to class II MHC-
associated diseases by enhancing IL-6 signaling in affected tissues
and cells like type 1 collagen+ cells (the fourth step), as non-
polarized activated CD4+ T cells, Th1, and IL-17A−/− Th17 cells
too induce a mild form of arthritis in F759 mice (Murakami
et al., 2011). TNFα, for example, may contribute to localized
class II MHC-associated autoimmune diseases via NF-κB acti-
vation followed by IL-6 ampliﬁer activation. In support of this
idea, numerous studies have demonstrated the efﬁcacy of targeting
TNFα when treating RA and other chronic autoimmune diseases,
the majority of which involve class II MHC molecules (Feldmann
and Maini, 2001). Furthermore, activated CD4+ T cells are known
to express TNFα (Cherwinski et al., 1987; Constant and Bottomly,
1997; Brennan et al., 2002; Williams et al., 2008), while we have
found a lack of TNFα attenuates arthritis in F759 mice (unpub-
lished data). Moreover, it is interesting that LPS administration
around the joints induces arthritis in mice that have an excess
number of Th1 cells (Nickdel et al., 2009). This may suggest that
LPS-mediated IL-6 production induces a local accumulation of
Th1 cells followed by activation of the IL-6 ampliﬁer.
ROLE OF COGNATE RECOGNITIONS BY CD4+ T CELLS
Activation of the IL-6 ampliﬁer is also involved in the develop-
ment of EAE (Ogura et al., 2008). Because the model for EAE is
dependent on tissue speciﬁc, MOG-derived peptides, these results
suggest that antigen speciﬁcity by effector CD4+ T cells and IL-6
ampliﬁer activation in the affected tissue do not always func-
tion independently of each other in tissue-speciﬁc autoimmune
diseases. If this is the case, cognate antigen-recognition by effec-
tor CD4+ T cells could occur upstream of the enhanced IL-6
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signaling in the affected tissue such that the antigen speciﬁcity
of the effector CD4+ T cells functions initially to target CD4+
T cells around said tissues. In other words, the antigen speciﬁcity
might bypass initial local events (like microbleeding) to induce
tissue-speciﬁc accumulation of activated T cells, although some
local events might increase the efﬁcacy of the tissue accumula-
tion even in diseases like EAE (step 2 in Figure 2). The resulting
pool of activated CD4+ T cells around the affected tissues could
enhance local IL-6 signaling, which would then act as a source for
cytokines via the IL-6 ampliﬁer. Thus, regardless of the stimulus
for the local accumulation of effector CD4+ T cells, the resulting
inﬂammatory disease is associated with class II MHC molecules
if cytokines from the activated CD4+ T cells are involved in the
disease development.
THE IL-6 AMPLIFIER BEYOND MHC CLASS II-ASSOCIATED
DISEASES AND DISORDERS
Indeed, MHC class II genes are associated with a number of
human diseases and disorders that extend beyond typical autoim-
mune diseases including metabolic syndrome, psychotic illnesses,
and other inﬂammatory diseases. Diseases and disorders in the
Genetic Association Database at the National Institute of Aging
(http://geneticassociationdb.nih.gov/cgi-bin/index.cgi) found to
be associated with the MHC class II genes described above are
wide and varied (Table 1). These associations and our four-step
model suggest that at least some subfamilies of these diseases and
disorders might be affected by the activation status of the IL-6
ampliﬁer, which is triggered by cytokines from CD4+ T cells.
However, we also hypothesize that the importance of the IL-6
ampliﬁer activation extends beyond MHC class II-associated dis-
eases and disorders to include those that arise from inﬂammation
induction. One reason is the ampliﬁer’s synergistic activation of
NF-κB and STAT3 in type 1 collagen+ cells. In other words, it is
possible that not all NF-κB and/or STAT3 stimulators are supplied
by activated CD4+ T cells. Therefore, chronic activation of NF-
κB and STAT3 induced by genetic and/or environmental factors
may give rise to similar effects exerted by chronic activation of
the IL-6 ampliﬁer. It is likely that activation of NF-κB and STAT3
by genetic and environmental factors other than T cell products
triggers certain chronic inﬂammatory diseases that are not read-
ily apparent to be associated with MHC class II genes. Examples
include adult Still’s disease and Castleman’s disease. Indeed, these
diseases do associate with the IL-18 gene (Sugiura et al., 2002), an
NF-κB stimulator, and with the IL-6 gene, suggesting perhaps that
IL-18- and IL-6-mediated IL-6 ampliﬁer activation plays a role.
In these cases, local events can determine the tissue speciﬁcity for
the development of diseases like F759 arthritis even in the absence
of tissue antigen-recognition by activated T cells (Hirano, 2010;
Murakami et al., 2011).
To summarize, we have investigated how MHC class II-
associated tissue-speciﬁc autoimmune arthritis develops and pro-
pose a four-step model to explain the process. This model provides
a possible explanation for why tissue-speciﬁc antigens recognized
by activated CD4+ T cells have not been identiﬁed in many tissue-
speciﬁc autoimmune diseases associated with class II MHC mole-
cules including RA. This may be explained by our four-step model,
which highlights the idea that the tissue itself can determine the
tissue speciﬁcity of the autoimmune disease. Additionally, genetic
and environmental factors affecting the target tissue are involved.
These results have led us to propose that direct activation of the
IL-6 ampliﬁer by STAT3 and NF-κB can result in chronic inﬂam-
matory diseases that are not apparently associated with MHC class
II. Thus, we expect our four-step model will provide new and
important insights on the immunologicalmechanisms that under-
lie autoimmune disease as well as other chronic inﬂammatory
diseases.
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Table 1 | The MHC class II genes are associated with various diseases and disorders.
Autoimmune diseases Celiac disease Crohn’s disease Grave’s disease Juvenile idiopathic arthritis Lupus/glomerulonephritis
Multiple sclerosis Rheumatoid
arthritis
Sjogren’s
syndrome
Thyroid autoimmunity Type 1 diabetes/IDDM
Metabolic
syndrome-related
diseases
Cholangitis Hypertension Lacunar stroke Sclerosing Type 2 diabetes/NIDDM
Psychotic illnesses Narcolepsy Schizophrenia
Inﬂammatory diseases Addison’s disease Allergies Asthma Atopy Cardiomyopathy
Dermatomyositis Endometriosis GVHD Hepatitis Inﬂammatory bowel disease
Liver cirrhosis Nasal polyposis Osteoarthritis Periodontitis Psoriasis
Recurrent
pregnancy loss
Sarcoidosis Ulcerative colitis Vitiligo
We investigated whether the MHC class II genes are associated with various diseases and disorders using the Genetic Association Database at the National Institute
of Aging.
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